Log In
Print this Print this

Blincyto, blinatumomab (AMG 103) (formerly MT103)

Also known as: formerly MEDI-538

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionBispecific T cell engager (BiTE) against CD19
Molecular Target CD19
Mechanism of ActionImmunotherapy; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today